PTPRC and melanoma: Tirosh et al. analyzed 4,645 single cells from 19 melanoma patients with a variety of clinical and therapeutic backgrounds, profiling malignant cells (CD45− and inferring CNVs) and non-malignant cells (CD45+ and inferring of CNVs): immune, stromal, and endothelial cells (112).